
Opinion|Videos|March 4, 2025
Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC
Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- When selecting third-line treatments for mCRC, how do you balance safety, efficacy, and overall patient prognosis?
- How do the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, and how can these differences inform treatment decisions?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
3
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
4
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
5














































